Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Japan
Clinical trial register · Japan

Clinical Trials in Japan

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2516 matching records held by the registry are in this view. Synced 12 Nov 2026, 03:19 UTC
2516
Studies in scope
all four open statuses
1285
Recruiting now
open to new participants
352
Lead sponsors
across recruiting studies
Top sites
Fukuoka 557 Nagoya 513 Sapporo 400 Tokyo 375 Osaka 354
Narrow the register
Recruitment status
Phase
Lead sponsor
AstraZeneca196 Eli Lilly and Company118 Novartis Pharmaceuticals106 AbbVie100 Merck Sharp & Dohme LLC100 Pfizer99 Janssen Research & Development, LLC78 GlaxoSmithKline74 Bristol-Myers Squibb69 China-Japan Friendship Hospital69 Boehringer Ingelheim52 Sanofi51 Takeda49 Amgen49 Hoffmann-La Roche47 Daiichi Sankyo43 Novo Nordisk A/S32 Bayer30 Ono Pharmaceutical Co., Ltd.27 Genmab21 Alexion Pharmaceuticals, Inc.19 Incyte Corporation19 Regeneron Pharmaceuticals18 Astellas Pharma Global Development, Inc.17 argenx16 Show all 535
Site location
Fukuoka557 Nagoya513 Sapporo400 Tokyo375 Osaka354 Chiba328 Kashiwa317 Yokohama272 Kobe239 Kyoto231 Hiroshima224 Sendai207 Chūōku202 Matsuyama172 Bunkyō City171 Kanazawa149 Kumamoto147 Okayama133 Kashiwa-shi132 Niigata120 Fukushima114 Kagoshima107 Kanagawa105 Aichi104 Gifu103 Show all 938
All 938 locations
Target enrolment
to

Trials in this register

2516 of 2516 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Not yet open
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Kurume-shi, Sapporo, Kumamoto, Kyoto, Matsumoto-shi, Suita-shi, Bunkyo-ku, Shinjuku-ku
2027-11-23
Not yet open
Boehringer Ingelheim
Phase 3
68
Saitama, Hidaka, Tokyo, Chuo-ku
2027-03-04
Not yet open
Chen Xiangmei
Phase 4
410
2027-03-01
Not yet open
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
92
Sapporo, Yokohama, Suita, Bunkyo-ku, Fukuoka, Maebashi, Okayama
2027-02-03
Not yet open
National Cancer Center, Japan
Phase 2
35
Yokohama, Chuo-ku
2027-02-01
Not yet open
National Cancer Center, Japan
Phase 2
32
Hyōgo, Saitama, Tokyo
2027-02-01
Not yet open
Bayer
Phase 2
8
Nagoya, Yokohama, Toyonaka, Bunkyo-ku, Kyoto
2027-01-25
Not yet open
Boehringer Ingelheim
Phase 3
1,500
Aichi, Nagoya, Aomori, Hirosaki, Chiba, Chiba, Chiba, Kamogawa, Fukuoka, Fukuoka, Hyogo, Himeji, Ibaraki, Naka-gun, Ibaraki, Tsukuba
2027-01-11
Not yet open
Novo Nordisk A/S
Phase 3
400
Suita-shi, Sakai-shi, Osaka, Shinjuku-ku, Tokyo, Tokyo
2027-01-07
Not yet open
National Cancer Center, Japan
Phase 2
27
Fukuoka, Hiroshima, Nagoya, Takatsuki, Tokyo
2027-01-01
Not yet open
Beijing Hospital of Traditional Chinese Medicine
Not applicable
240
2027-01
Not yet open
Bristol-Myers Squibb
Phase 3
2,380
Nagoya, Seto-shi, Kamogawa-Shi, Eiheiji-cho, Yoshida-gun, Chikushino-shi, Fukuoka, Iizuka-shi, Kurume-Shi
2026-12-16
Not yet open
Boehringer Ingelheim
Phase 3
270
Aichi, Nagoya, Fukuoka, Kitakyushu, Fukushima, Fukushima, Hokkaido, Sapporo, Kanagawa, Kawasaki, Kanagawa, Yokohama, Kyoto, Kyoto, Miyagi, Sendai
2026-12-14
Not yet open
Boehringer Ingelheim
Phase 1
200
Osaka, Hirakata, Tokyo, Koto-ku
2026-12-07
Not yet open
Eli Lilly and Company
Phase 3
3,000
Hamadayama, Suginami-ku, Himeji, Kisarazu, Kōriyama, Kumamoto, Kurume, Osaka, Shinjyuku
2026-12
Not yet open
Eli Lilly and Company
Phase 3
2,115
Chiyoda City, Chūōku, Kawasaki, Kin-cho, Kunigami-gun, Nerima-ku, Shinjuku, Shinjuku-ku, Urasoe
2026-12
Not yet open
A Study of LY4336619 in Adult Participants With Advanced Solid Tumors
NCT07928258Endometrial Neoplasms, Ovarian Neoplasms, Neoplasms, Germ Cell and Embryonal, Carcinoma, Non-Small-Cell Lung
DrugSofe-M
Eli Lilly and Company
Phase 1
370
Shizuoka, Tokyo
2026-12
Recruiting
Baduanjin Rehabilitation for Functional Restoration in ICI-Associated Myocarditis
NCT07280429Immune Checkpoint Inhibitors Related Myocarditis
China-Japan Friendship Hospital
Not applicable
60
2026-12
Not yet open
Bristol-Myers Squibb
Phase 2
80
Kitakyushu, Yokohama, Ōsaka-sayama
2026-11-30
Not yet open
Tezepelumab CRSwNP Real World Study (CREW Study)
NCT07790198Chronic Rhinosinusitis With Nasal Polyps
DrugTezepelumab
AstraZeneca
Observational
100
Chiba, Fukui, Fukuoka, Gunma, Hiroshima, Hokkaido, Hyōgo, Ishikawa
2026-11-30
Not yet open
Effect of MxA Guidance on Antiviral Treatment in Respiratory Viral Infections
NCT07892872Respiratory Viral Infections, Influenza, SARS CoV 2 Infection
Capital Medical University
Not applicable
618
2026-11-30
Not yet open
Real-world Outcome of Zongertinib in Japan (J-HERZ)
NCT07926308Non-small Cell Lung Cancer
DrugZongertinib
Boehringer Ingelheim
Observational
300
Tokyo
2026-11-17
Not yet open
Boehringer Ingelheim
Phase 2
70
Fukui, Yoshida-gun, Fukuoka, Fukuoka, Hokkaido, Sapporo, Kanagawa, Yokohama, Kumamoto, Kumamoto, Osaka, Sakai, Shizuoka, Hamamatsu
2026-11-13
Not yet open
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 2
80
2026-11-13
Not yet open
Novo Nordisk A/S
Phase 3
1,408
Yamato-shi, Arakawa-ku, Tokyo, Okayama, Sendai-shi, Miyagi, Tokyo
2026-11-11
Recruiting
Boehringer Ingelheim
Phase 1
90
Tokyo, Koto-ku
2026-11-10
Not yet open
Nanjing Zenshine Pharmaceuticals
Phase 3
858
2026-11-07
Recruiting
argenx
Phase 2
120
Fukuoka, Sapporo
2026-11-05
Recruiting
The Clinical Trial of Tamibarotene for Patients With HFpEF (RELIEF Trial)
NCT07855692HFpEF - Heart Failure With Preserved Ejection Fraction
DrugTamibarotene
Nagoya University
Phase 2
90
Nagoya, Ōbu, Tsu, Tokyo
2026-11-05
Not yet open
China National Center for Cardiovascular Diseases
Phase 3
270
2026-11-01
Not yet open
First Hospital of China Medical University
Observational
2,400
2026-11-01
Not yet open
Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)
NCT07521670Recurrent Adenoid Cystic Carcinoma, Adenoid Cystic Carcinoma Metastatic, Papillary Thyroid Carcinoma
DrugSacituzumab tirumotecan
National Cancer Centre, Singapore
Phase 2
68
Tokyo
2026-11
Not yet open
HISTOACRYL® Used for Embolization of Thoracoabdominal Artery Bleeding
NCT07753005Hemorrhage, Gastrointestinal Hemorrhage, Hemoptysis, Postpartum Hemorrhage
Aesculap AG
Observational
176
Nagoya, Toyoake, Kashiwa, Gifu, Sapporo, Nishinomiya, Kawasaki, Kashihara
2026-11
Not yet open
Ono Pharmaceutical Co., Ltd.
Phase 2
18
Tokyo
2026-10-31
Recruiting
Novartis Pharmaceuticals
Phase 2
120
Yokohama, Suita, Hachiōji, Shinjuku-ku, Fukushima, Niigata
2026-10-30
Not yet open
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT07707895Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
DrugsZL-1310·Obrixtamig·Atezolizumab
Boehringer Ingelheim
Phase 1/2
60
Hokkaido, Sapporo, Kanagawa, Kawasaki, Osaka, Hirakata, Shizuoka, Sunto-gun
2026-10-28
Not yet open
Capital Medical University
Phase 3
600
2026-10-28
Recruiting
Takeda
Phase 2
36
Nagoya, Kumamoto, Shinjuku-ku, Niigata, Osaka
2026-10-27
Recruiting
Smartphone Enabled Detection of Cognitive Motor Dissociation in the ICU
NCT07917728Traumatic Brain Injury (TBI) Patients, Intracerebral Hemorrhage, Subarachnoid Hemorrhage, Cardiac Arrest (CA)
Columbia University
Observational
240
Tsukuba, Asaka
2026-10-27
Not yet open
Novo Nordisk A/S
Phase 3
8,500
Chiba-shi, Chiba, Fuchu-shi,Tokyo, Fukuoka, Himeji-shi, Hyogo, Hyōgo, Kanagawa, Kumamoto-shi, Kumamoto, Kyoto-shi, Kyoto
2026-10-26
Not yet open
Capital Medical University
Phase 2/3
570
2026-10-21
Recruiting
Novo Nordisk A/S
Phase 3
84
Hirakata-shi, Osaka, Maebashi-shi, Gunma, Nara, Niigata-shi, Niigata, Nishinomiya-shi, Hyogo, Tokyo
2026-10-16
Recruiting
Eli Lilly and Company
Phase 3
1,000
Chūōku, Narashino, Sōka, Tsuchiura
2026-10-16
Not yet open
De Novo Gastroesophageal Reflux Disease After Sleeve Gastrectomy With and Without Omentopexy
NCT07854613Omentopexy, Sleeve Gastrectomy, Gastroesophageal Reflux Disease
China-Japan Friendship Hospital
Not applicable
140
2026-10-15
Recruiting
Pfizer
Phase 3
600
Sapporo, Akashi, Hidaka, Koto-ku, Fukushima, Niigata
2026-10-14
Recruiting
A Study of DS-3939a in Participants With Solid Tumors
NCT07739966Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
DrugsDS-1103a·DS-3939a·Pemetrexed·Carboplatin
Daiichi Sankyo
Phase 1/2
400
Hirakata, Kashiwa-shi, Matsuyama, Sendai, Shiroishi-ku, Sapporo-shi
2026-10-13
Not yet open
Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
Phase 2
160
2026-10-10
Recruiting
AIMEDBIO
Phase 1
86
Tokyo, Chuo-ku
2026-10-09
Recruiting
Novartis Pharmaceuticals
Observational
80
Toyoake, Fukuoka, Kyoto, Kodaira
2026-10-07
Recruiting
Bristol-Myers Squibb
Phase 3
176
Miyakonojō, Kashihara, Hirakata, Yoshinogari-cho, Kanzaki-gun, Ōta-ku, Yokohama, Kanagawa
2026-10-06
Recruiting
Hoffmann-La Roche
Phase 3
400
Gifu, Hiroshima, Hyōgo, Ōita
2026-10-06
Recruiting
Janssen Research & Development, LLC
Phase 2
440
Sapporo, Shinagawa City
2026-10-05
Recruiting
Hoffmann-La Roche
Phase 3
1,600
Aichi, Hyōgo, Tokyo
2026-10-02
Recruiting
Pfizer
Phase 3
180
Mihama-ku, Matsuyama, Fukuoka, Kasuya-gun, Sapporo, Amagasaki, Mito, Naka
2026-10-02
Recruiting
GlaxoSmithKline
Phase 3
720
Niigata, Osaka
2026-10-02
Recruiting
Kiminori Kimura, MD
Phase 2
7
Sapporo, Sendai, Osaka, Bunkyo-Ku
2026-10-01
Recruiting
Risankizumab for Refractory Perianal Fistulizing Crohn's Disease
NCT07872449Crohn Disease, Perianal Fistula, Perianal Fistula Due to Crohn's Disease, Perianal Crohn's Disease
DrugRisankizumab
Yuki Horio
Phase 4
25
Nishinomiya, Shinjuku-Ku, Yokohama
2026-10-01
Not yet open
Shanghai Mental Health Center
Observational
500
2026-10-01
Recruiting
Boehringer Ingelheim
Phase 1/2
55
Okayama, Okayama, Osaka, Hirakata, Shizuoka, Sunto-gun
2026-10-01
Not yet open
CTEPH Differential Diagnosis Assisted by Enhanced Large Language Model Support
NCT07902011Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Acute Pulmonary Embolism (PE), Pulmonary Artery Sarcoma
China-Japan Friendship Hospital
Not applicable
60
2026-10-01
Not yet open
Eli Lilly and Company
Phase 1
60
Fukuoka, Sumida-ku, Toshima City
2026-10
Not yet open
Study of BK1803 in Healthy Infants
NCT07793513Pertussis, Diphtheria, Tetanus, Poliomyelitis
Tanabe Pharma Corporation
Phase 3
344
Fukui-shi, Fukuoka, Isesaki, Maebashi, Hiroshima, Ishikari-shi, Sapporo, Amagasaki
2026-10
Not yet open
Breast Cancer Trials, Australia and New Zealand
Not applicable
150
Okayama
2026-10
Not yet open
A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)
NCT07843459Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
Eli Lilly and Company
Phase 1
111
Bunkyō City, Ōbu
2026-10
Recruiting
Safety and Efficacy Study of Sivelestat in Neuromyelitis Optica Spectrum Disorder
NCT07738952Neuromyelitis Optica Spectrum Disorder Attack
Kyushu University
Phase 1/2
7
Fukuoka
2026-10
Recruiting
Kyushu University
Phase 1
21
Fukuoka
2026-10
Not yet open
Head-to-Head (H2H) Comparison of Ambulatory Cardiac ECG Monitors in Japan
NCT07870837Atrial Fibrillation (AF), Atrial Flutter, Supraventricular Tachycardia (SVT), Ventricular Tachycardia (VT)
iRhythm Technologies, Inc.
Not applicable
130
Gifu, Nagoya
2026-09-30
Recruiting
China-Japan Friendship Hospital
Not applicable
208
2026-09-30
Recruiting
Pfizer
Phase 3
197
Mihama-ku, Matsuyama, Fukuoka, Kasuya-gun, Sapporo, Amagasaki, Mito, Naka
2026-09-29
Recruiting
NS Pharma, Inc.
Phase 2
135
Kitakyushu
2026-09-29
Recruiting
GlaxoSmithKline
Phase 3
218
Gunma, Nagano
2026-09-28
Recruiting
A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT07441278Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
DrugNS-863
NS Pharma, Inc.
Phase 2
177
Kitakyushu
2026-09-28
Recruiting
AstraZeneca
Phase 3
750
Nagoya
2026-09-24
Recruiting
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
NCT07816666Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
DrugsTorvutatug samrotecan·Bevacizumab
AstraZeneca
Phase 3
600
Chiba, Fukuoka, Fukushima, Gifu, Hidaka-shi, Ichihara, Kagoshima, Kobe
2026-09-24
Recruiting
GlaxoSmithKline
Phase 3
610
Fukuoka, Fukushima, Hokkaido, Ibaraki, Miyagi, Numakunai, Osaka, Saitama
2026-09-24
Recruiting
Pfizer
Phase 3
920
Maebashi, Midori, Chuo-ku
2026-09-22
Recruiting
Novartis Pharmaceuticals
Phase 3
382
Yokohama, Kamimashiki-gun
2026-09-21
Not yet open
Treatment Strategy for Patients With RA-ILD
NCT07643038Rheumatoid Arthritis Associated Interstitial Lung Disease
DrugsTocilizumab·Methotrexate·Rituximab
Chinese SLE Treatment And Research Group
Phase 4
204
2026-09-20
Recruiting
Novartis Pharmaceuticals
Phase 2
180
Kasugai, Matsudo, Kamakura, Matsubara
2026-09-18
Recruiting
4D Molecular Therapeutics
Phase 3
514
Mito, Amagasaki-shi, Fukuoka, Fukushima, Hachioji-shi, Kagoshima, Kita-Gun, Kobe
2026-09-18
Recruiting
Daiichi Sankyo
Phase 1/2
220
Kashiwa, Isehara, Yokohama, Hirakata, Chuo-ku, Koto-ku, Shinagawa-ku, Fukuoka
2026-09-17
Recruiting
Boehringer Ingelheim
Phase 3
466
Aichi, Seto, Fukuoka, Fukuoka, Fukuoka, Kitakyushu, Hiroshima, Hiroshima, Hokkaido, Sapporo, Kagawa, Kita-gun, Kanagawa, Yokohama, Osaka, Sakai
2026-09-17
Recruiting
Antengene Biologics Limited
Phase 3
380
2026-09-17
Recruiting
Merck Sharp & Dohme LLC
Phase 2
6
Izumi, Suita, Setagaya City
2026-09-17
Recruiting
Janssen Research & Development, LLC
Phase 2
100
Kobe
2026-09-16
Recruiting
UCB Biopharma SRL
Phase 3
100
Kobe, Minatoku, Sendai
2026-09-16
Recruiting
AstraZeneca
Phase 3
950
Fukushima, Ginowan-shi, Hidaka-shi, Isehara-shi, Kashiwa-shi, Kawasaki-shi, Kobe, Kōtoku
2026-09-16
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 1/2
50
Chiba, Kashiwa, Fukuoka, Hiroshima, Sapporo, Kanazawa, Yokohama, Kyoto
2026-09-15
Recruiting
AstraZeneca
Phase 3
1,330
Chiba, Fukuoka, Hiroshima, Kamakura-shi, Kawagoe-shi, Kisarazu-shi, Kita-gun, Kobe
2026-09-15
Recruiting
Shionogi
Phase 3
2,000
Kasugai-Shi, Chiba, Fukuoka, Nihommatsu, Annaka-Shi, Fujioka-Shi, Koyagimachi, Maebashi
2026-09-14
Recruiting
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC
NCT07733180Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma
DrugsLeucovorin·Adrucil·Tislelizumab·Oxaliplatin
BeOne Medicines
Phase 2
30
Yokohama, Takatsukishi, ChuoKu, Osaka
2026-09-14
Recruiting
Takeda
Phase 3
324
Chiba, Toon-shi, Kobe, Hitachi, Tsu, Miyazaki, Bunkyo-Ku, Chuo-shi
2026-09-10
Recruiting
GlaxoSmithKline
Phase 1/2
184
Osaka
2026-09-09
Not yet open
Bloomage Biotechnology Corp., Ltd.
Not applicable
90
Nerima-ku, Shinagawa-ku
2026-09-09
Recruiting
Eli Lilly and Company
Phase 1
179
Bunkyō City, Ōbu
2026-09-09
Recruiting
Spinal Cord Stimulation for Poststroke Spasticity
NCT07744659Spasticity Post Stroke
Beijing Pins Medical Co., Ltd
Not applicable
92
2026-09-09
Recruiting
Bristol-Myers Squibb
Phase 3
850
Nagoya, Toon-Shi, Kurume-Shi, Yokohama, Sendai, Okayama, Hirakata-Shi, Osakasayama-Shi
2026-09-08
Recruiting
Incyte Corporation
Phase 3
426
Bunkyō City, Chūō, Fukuoka, Fukushima, Hirakata, Kagoshima, Kashiwa-shi, Kobe
2026-09-08
Recruiting
GlaxoSmithKline
Phase 3
690
Hokkaido, Hyōgo, Ibaraki
2026-09-08
Recruiting
A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors
NCT07801508Advanced Gastroesophageal Adenocarcinoma, Advanced Breast Cancer, Triple-negative Breast Cancer, Advanced Non-small Cell Lung Cancer
Novartis Pharmaceuticals
Phase 1
66
Kyoto
2026-09-08
Recruiting
Novo Nordisk A/S
Phase 3
400
Sapporo, Yamato-shi, Chigasaki-shi, Kawasaki-shi, Suita-shi, Aichi, Bunkyo-ku, Tokyo, Chiba
2026-09-07
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1/2
392
Chuo-ku, Koto-ku
2026-09-02
Not yet open
Breakthrough Platform Trial for PCAS
NCT07769086Cardiac Arrest (CA), Post Cardiac Arrest Syndrome
Kagawa University
Not applicable
630
Chiba, Iizuka, Hiroshima, Kobe, Kita-gun, Kyoto, Sendai, Okayama
2026-09-01
Recruiting
AstraZeneca
Phase 3
2,800
Ageo, Asahi-shi, Chiba, Fukaya, Fukui-shi, Izumisano, Izunokuni-shi, Kariya
2026-09-01
Recruiting
GlaxoSmithKline
Phase 3
684
Tokyo, Tottori
2026-09-01
Recruiting
AbbVie
Phase 2
150
Kobe
2026-09-01
Recruiting
Long-term Safety Study Following to JRM-001 Treatment in Pediatric Patients With Congenital Heart Disease
NCT07884318Single Ventricle, Hypoplastic Left Heart Syndrome (HLHS)
Metcela Inc.
Observational
40
Okayama
2026-09-01
Recruiting
Oslo University Hospital
Observational
400
Nagoya, Tōon
2026-09
Not yet open
Kyoto University, Graduate School of Medicine
Observational
10,000
Kyoto
2026-09
Not yet open
Shanghai Ark Biopharmaceutical Co., Ltd.
Phase 3
263
2026-08-31
Recruiting
AstraZeneca
Phase 2
24
Ginowan-shi, Kagoshima, Kanazawa, Niigata, Setagaya-ku
2026-08-31
Recruiting
AstraZeneca
Phase 3
1,072
Fukuoka, Kanazawa, Maebashi, Nagoya, Sapporo, Yokohama
2026-08-31
Recruiting
Amgen
Phase 3
400
Bunkyo-ku
2026-08-28
Recruiting
Genmab
Phase 3
688
Tokyo, Chuo Ku Niigata, Tokushima, Yamagata
2026-08-28
Recruiting
Eli Lilly and Company
Phase 2
120
Hachiōji, Kamakura-shi, Naka, Narita
2026-08-27
Recruiting
GlaxoSmithKline
Phase 3
624
Fukuoka, Tokyo
2026-08-27
Recruiting
Regeneron Pharmaceuticals
Phase 3
1,600
Isehara-Shi, Shinjuku, Ube
2026-08-26
Recruiting
Eli Lilly and Company
Phase 3
2,001
Chūōku, Suita-shi, Tsuchiura
2026-08-26
Recruiting
Pfizer
Phase 3
1,375
Nagoya, Yahaba-cho, Yokohama, Habikino, Sakai, Shimotsuga-gun, Chuo-ku, Tachikawa
2026-08-24
Recruiting
Novartis Pharmaceuticals
Phase 3
180
Kitakyushu, Yokohama, Kumamoto, Habikino, Sakai, Tachikawa
2026-08-24
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Aomori, Chikushino-shi, Chūōku, Fukui-shi, Fukushima, Higashiibaraki-gun, Higashiohmi-shi, Iwakuni-shi
2026-08-24
Recruiting
AstraZeneca
Phase 3
500
Chūōku, Ichinomiya-shi, Izunokuni-shi, Kamakura-shi, Kawagoe-shi, Kitakyushu-shi, Kyoto, Mito
2026-08-24
Not yet open
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3
309
2026-08-24
Recruiting
AbbVie
Phase 3
300
Osaka
2026-08-24
Recruiting
Juro Sciences Inc.
Phase 2
70
Nagoya, Ōbu, Katori-shi, Yoshida-gun, Sapporo, Mito, Chiyoda-ku, Meguro-ku
2026-08-22
Recruiting
AstraZeneca
Phase 3
7,000
Aira, Akita, Asahikawa-shi, Chūōku, Fujisawa-shi, Fukuoka, Hachioji-shi, Hamamatsu
2026-08-21
Recruiting
AstraZeneca
Phase 3
1,500
Aira, Chūōku, Fukuoka, Hachioji-shi, Izunokuni-shi, Kumamoto, Nagoya, Nerima-ku
2026-08-20
Recruiting
Pfizer
Phase 3
1,100
Minamiku, Shinagawa, Hiroshima
2026-08-20
Recruiting
AstraZeneca
Phase 3
2,500
Chūōku, Fukuoka, Hachioji-shi, Osaka, Shibuya-ku, Takatsuki-shi
2026-08-19
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
356
Fukuoka, Hiroshima, Sapporo, Akashi, Yokohama, Tokyo, Natori-shi, Niigata
2026-08-19
Recruiting
Stemline Therapeutics, Inc.
Phase 2
70
Chiba, Fukuoka, Hirakata, Hiroshima, Ina, Isehara, Kagoshima, Kōtō City
2026-08-18
Recruiting
VarmX B.V.
Phase 3
800
Kamakura-Shi, Fukuoka-Shi, Fukuoka, Kumamoto-shi, Kumamoto
2026-08-18
Recruiting
Pfizer
Phase 3
375
Matsudo, Teine-ku, Nagaoka, Sakai, Shinagawa, Osaka
2026-08-17
Recruiting
AbbVie
Phase 2
168
Yokohama, Osaka, Chuo-Ku
2026-08-17
Recruiting
GlaxoSmithKline
Phase 2
24
Fukuoka, Hokkaido, Tokyo
2026-08-17
Not yet open
Nanjing IASO Biotechnology Co., Ltd.
Phase 1/2
27
2026-08-15
Recruiting
Eli Lilly and Company
Phase 3
1,000
Fukuoka, Hakata-Ku, Hino, Karatsu, Kawasaki, Kitakyushu, Koshigaya, Kōtō City
2026-08-14
Recruiting
Chengdu Kangnuoxing Biopharma,Inc.
Phase 3
136
2026-08-13
Recruiting
Genmab
Phase 1
112
Hirakata, Chuo Ku, Koto-Ku
2026-08-13
Recruiting
Alkermes, Inc.
Phase 3
150
Kumamoto
2026-08-13
Recruiting
National Cancer Center, Japan
Phase 2
29
Saitama, Tokyo, Yokohama
2026-08-13
Recruiting
A Study of LY3971297 in Participants With Heart Failure
NCT07547540Heart Failure, Heart Failure, Diastolic, Heart Failure, Systolic
Eli Lilly and Company
Phase 1
90
Kobe, Kyoto, Suita-shi, Tsuchiura-shi
2026-08-11
Recruiting
Regeneron Pharmaceuticals
Phase 3
15,364
Sapporo, Kawanishi, Higashiibaraki District, Tsuchiura, Yokohama, Kyoto, Kanagawa
2026-08-10
Recruiting
Eli Lilly and Company
Phase 2
606
Chūōku, Fukuoka, Iizuka, Osaka, Sendai, Ube
2026-08-07
Recruiting
First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors
NCT07681882Advanced Solid Tumor, Metastatic Solid Tumor, Unresectable Solid Tumor
Daiichi Sankyo
Phase 1
45
Kashiwa, Osaka, Tokyo
2026-08-06
Recruiting
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
NCT07498335Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy
DrugAtrasentan
Novartis Pharmaceuticals
Phase 3
28
Nagoya, Kanazawa, Chiba, Fukuoka
2026-08-06
Recruiting
Shionogi
Phase 3
1,200
Multiple Locations
2026-08-05
Recruiting
AbbVie
Observational
100
Iruma-gun, Bunkyo-ku, Kanagawa, Tokushima, Tokyo
2026-08-03
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
30
Osaka
2026-08-01
Not yet open
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2
40
2026-08-01
Not yet open
China-Japan Friendship Hospital
Phase 1/2
120
2026-08-01
Not yet open
Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis
NCT07722507Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Bristol-Myers Squibb
Observational
40
Tokyo
2026-08-01
Recruiting
VectivBio AG
Phase 3
124
Yokohama, Saga, Kagawa
2026-08
Not yet open
Prefectural University of Hiroshima
Not applicable
15
Mihara, Ibaraki
2026-08
Recruiting
AbbVie
Phase 2
2,000
Kure
2026-07-31
Not yet open
Kringle Pharma, Inc.
Phase 3
10
Iizuka, Bibai, Musashimurayama
2026-07-31
By invitation
Effect of Surgical Masks in Preventing Acute Respiratory Infections
NCT07739446Acute Respiratory Infections (ARIs), Influenza, COVID - 19
Chiba University
Not applicable
2,400
Chiba
2026-07-31
Recruiting
China-Japan Friendship Hospital
Not applicable
100
2026-07-30
Recruiting
Pfizer
Phase 3
336
Kitakyushu-shi, Hamamatsu, Koto-ku, Mitaka, Shinjuku-ku, Niigata, Osaka
2026-07-30
Recruiting
Amgen
Phase 3
950
Matsuyama, Kitakyusyu-shi, Aki-gun, Mito, Naka, Tsuchiura-shi, Kumamoto, Kashiwara-shi
2026-07-29
Recruiting
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
NCT07673887Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsASP2138·Folinic acid·Adrucil·Capecitabine
Astellas Pharma Global Development, Inc.
Phase 3
570
Kashiwa, Matsuyama, Sapporo, Akashi, Chuo-ku, Koto-ku, Niigata, Osaka
2026-07-28
Recruiting
Bristol-Myers Squibb
Phase 2
254
Chuo-ku
2026-07-27
Recruiting
Boehringer Ingelheim
Phase 3
448
Aichi, Nagoya, Aichi, Toyoake, Fukuoka, Kitakyushu, Gifu, Gifu, Hiroshima, Hiroshima, Hokkaido, Sapporo, Ishikawa, Kanazawa, Kagawa, Kita-gun
2026-07-27
Recruiting
GlaxoSmithKline
Phase 3
800
Ehime, Fukuoka, Gifu, Hokkaido, Kanagawa, Osaka, Tokyo, Toyama
2026-07-27
Recruiting
AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer
NCT07617337ALK Positive Non-small Cell Lung Cancer
DrugLorlatinib
Chugai Pharmaceutical
Phase 1
102
Nagoya, Kashiwa, Sakai, Nagaizumi-cho, Chuo-ku, Koto-Ku
2026-07-24
Recruiting
Janssen Research & Development, LLC
Phase 3
348
Akita, Karatsu, Kawasaki, Kobe, Kodaira, Koshigaya, Maebashi, Minatoku
2026-07-23
Recruiting
Amgen
Phase 3
3,200
Yokohama, Chiyoda-ku, Chuo-ku, Hachioji-shi, Minato-ku, Shinjuku-ku, Suginami-ku
2026-07-23
Recruiting
GlaxoSmithKline
Phase 3
380
Ōgaki, Kawasaki-shi
2026-07-22
Recruiting
GlaxoSmithKline
Phase 3
1,740
Ōgaki, Kawasaki-shi
2026-07-22
Recruiting
Insmed Incorporated
Phase 3
344
Chiba, Narashino, Yahatanishi-ku, Kita Kyushu-shi, Sapporo, Kobe, Okayama, Minato-ku, Mitaka-shi
2026-07-21
Recruiting
Boehringer Ingelheim
Phase 3
35
Fukuoka, Fukuoka, Osaka, Izumi, Tokyo, Setagaya-ku
2026-07-21
Active, closed
Boehringer Ingelheim
Phase 1
48
Fukuoka, Fukuoka, Tokyo, Sumida-ku
2026-07-21
Recruiting
Insmed Incorporated
Phase 3
344
Narita, Yokohama
2026-07-20
Recruiting
AstraZeneca
Phase 3
915
Fukuoka, Hamamatsu, Hirosaki-shi, Kanazawa, Kashihara-shi, Kawasaki-shi, Kita-gun, Kobe
2026-07-16
Recruiting
Bayer
Observational
40
Many Locations
2026-07-16
Recruiting
National Cancer Center, Japan
Phase 2
136
Chiba, Fukuoka, Gifu, Maebashi, Hiroshima, Kawasaki, Yokohama, Ina
2026-07-15
Recruiting
GlaxoSmithKline
Phase 4
28
Ehime, Fukui, Fukuoka, Gunma, Nagano, Osaka, Saitama, Shiga
2026-07-15
Recruiting
UCB BIOSCIENCES, Inc.
Phase 3
200
Chiyoda-ku, Kodaira, Kurume, Musashimurayama-shi, Osaka, Setagaya-ku
2026-07-14
Recruiting
Takeda
Phase 2
9
Nagoya, Maebashi, Tsu, Suita, Bunkyo-ku, Shinjuku-ku, Sumida-ku, Chūō
2026-07-14
Recruiting
Gilead Sciences
Phase 3
590
Osaka
2026-07-14
Recruiting
China-Japan Friendship Hospital
Not applicable
120
2026-07-14
Recruiting
Non-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis(EROSION IV)
NCT07567625Acute Myocardial Infarction (AMI), ST-Segment Elevation Myocardial Infarction(STEMI), Non-ST-Segment Elevation Myocardial Infarction(NSTEMI)
Harbin Medical University
Not applicable
2,000
2026-07-13
Recruiting
Boehringer Ingelheim
Phase 3
390
Aichi, Nagoya, Chiba, Kashiwa, Ehime, Matsuyama, Fukuoka, Fukuoka, Hokkaido, Sapporo, Ishikawa, Kanazawa, Kanagawa, Yokohama, Kyoto, Kyoto
2026-07-10
Recruiting
argenx
Phase 2
40
Hanamaki, Sendai
2026-07-10
Recruiting
Metagen Therapeutics, Inc.
Phase 1/2
54
Fukuoka, Sapporo, Kurashiki, Hirakata, Hamamatsu, Bunkyō-Ku, Minato-Ku, Mitaka
2026-07-09
Recruiting
AstraZeneca
Phase 3
600
Asahikawa-shi, Kamakura-shi, Kashiwa-shi, Kobe, Komoro, Kumamoto, Kyoto, Miyazaki
2026-07-08
Recruiting
Eli Lilly and Company
Phase 3
170
Chiyoda-ku, Fukuoka, Iruma, Moriyama, Niigata, Osaka, Saitama, Sendai
2026-07-08
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 1
10
Kashiwa, Tokyo
2026-07-07
Recruiting
AstraZeneca
Phase 3
1,200
Asahikawa-shi, Chūōku, Kamakura-shi, Koga-shi, Kumamoto, Mitaka-shi, Mito, Miyazaki
2026-07-06
Recruiting
AstraZeneca
Phase 3
2,000
Chūōku, Fukuoka, Hachioji-shi, Ichikawa-shi, Kamakura-shi, Kishiwada-shi, Kitakyushu, Meguro-ku
2026-07-06
Recruiting
AstraZeneca
Phase 3
900
Chigasaki-shi, Chikushino-shi, Gifu, Kagoshima, Kitakyushu, Kumamoto, Kyoto, Maebashi
2026-07-06
Recruiting
AstraZeneca
Phase 3
800
Amagasaki-shi, Chiba, Chitose-shi, Chūōku, Koga-shi, Minatoku, Okayama, Oyama-shi
2026-07-06
Recruiting
Novartis Pharmaceuticals
Phase 1
64
Sumida Ku
2026-07-02
Recruiting
AbbVie
Phase 3
531
Toyoake, Hirosaki, Fukuoka, Sapporo, Kobe, Sagamihara-shi, Sendai, Niigata
2026-07-02
Recruiting
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
NCT07476287Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms
DrugPF-08634404
Pfizer
Phase 2
40
Nagoya, Kita, Hirakata, Chūō, Kotoku, Osaka
2026-07-02
Recruiting
Kowa Company, Ltd.
Phase 4
120
Hokkaido, Ibaraki, Kagawa, Kanagawa, Osaka, Saitama, Tokyo
2026-07-01
Recruiting
Lefamulin Post-Market Surveillance Study
NCT07697885Community-Acquired Pneumonia (CAP)
Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Observational
1,000
2026-06-30
Recruiting
Merck Sharp & Dohme LLC
Phase 2
750
Suita, Arakawa City, Hachiōji, Katsushika-ku, Musashino, Shinjuku, Fukuoka, Nagasaki
2026-06-30
Active, closed
AstraZeneca
Phase 1
18
Sumida-ku
2026-06-29
Recruiting
AstraZeneca
Phase 3
4,500
Amagasaki-shi, Chūōku, Kasugai-shi, Koga-shi, Maebashi, Minatoku, Naka, Shinjuku-ku
2026-06-29
Active, closed
GlaxoSmithKline
Phase 3
102
Aichi, Chiba, Fukui, Fukuoka, Fukushima, Hokkaido, Kanagawa, Kyoto
2026-06-29
Recruiting
AstraZeneca
Phase 3
750
Fukuoka, Kyoto, Nishinomiya-shi, Okayama, Sapporo, Shibuya-ku, Shinjuku-ku, Suita-shi
2026-06-26
Recruiting
Chiesi Farmaceutici S.p.A.
Phase 3
554
2026-06-26
Recruiting
ViiV Healthcare
Phase 3
564
Aichi, Kanagawa, Osaka, Tokyo
2026-06-25
Recruiting
Taiho Pharmaceutical Co., Ltd.
Phase 3
784
Aichi, Fukuoka, Hokkaido, Kanagawa, Miyagi, Osaka, Tokyo, Toyama
2026-06-24
Recruiting
Hoffmann-La Roche
Phase 3
380
Toyohashi, Aichi, Ehime, Gunma, Hyōgo, Kyoto, Numakunai, Okayama
2026-06-23
Recruiting
Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
NCT07630961Metastatic Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC), HR+/HER2- Ductal Breast Cancer (BC), HR+/HER2- Lobular Breast Cancer (BC)
Drug68Ga-NNS309
Novartis Pharmaceuticals
Phase 1
66
Chuo Ku
2026-06-23
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
20
Nagoya, Sapporo, Kobe, Chūō, Fukuoka, Kyoto
2026-06-23
Recruiting
GlaxoSmithKline
Phase 1/2
64
Fukuoka, Hokkaido, Tokyo
2026-06-22
Recruiting
Immunomic Therapeutics, Inc.
Phase 1
45
Tokyo
2026-06-20
Recruiting
Sun Pharma Japan Limited
Phase 3
78
Asahikawa, Bunkyō City, Ebina, Hamamatsu, Ishikawa, Kitakyushu, Kōtoku, Kurashiki
2026-06-19
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 1
80
Kashiwa, Maebashi, Niigata, Hirakata, Osaka, Sakai, Hidaka, Sunto-gun
2026-06-19
Recruiting
GlaxoSmithKline
Phase 1/2
49
Aichi, Chiba, Tokyo
2026-06-19
Recruiting
Merck Sharp & Dohme LLC
Phase 1
120
Chūō
2026-06-18
Recruiting
Yonsei University
Not applicable
748
Osaka
2026-06-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
310
Ōta, Sapporo, Kobe, Matsusaka, Sendai, Shimotsugagun
2026-06-18
Recruiting
GlaxoSmithKline
Phase 3
450
Fukuoka, Hokkaido, Hyōgo, Kanagawa, Mie, Okinawa, Osaka, Saitama
2026-06-18
Recruiting
Vantive Health LLC
Observational
750
2026-06-17
Recruiting
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
NCT07660055Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Gastric/Gastroesophageal Junction (GEJ) Cancer, Bladder Cancer
Novartis Pharmaceuticals
Phase 1
156
Kashiwa
2026-06-16
Recruiting
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)
NCT07637734Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Verrica Pharmaceuticals Inc.
Phase 3
300
Sapporo, Kamimashiki-gun, Kumamoto, Sakai, Saitama, Tokyo
2026-06-15
Active, closed
AstraZeneca
Phase 2
326
Bunkyō City, Kurume-shi, Sapporo, Shinjuku-ku, Suita
2026-06-11
Recruiting
A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia
NCT07646678Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2
DrugTAK-360
Takeda
Phase 2/3
500
Yokohama, Kumamoto, Isahaya-shi, Urasoe, Osaka, Shinjuku-ku
2026-06-11
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Fukuoka, Hachioji-shi, Hamamatsu, Hiroshima, Kakogawa-shi, Kumagaya-shi, Kumamoto, Matsusaka-shi
2026-06-11
Recruiting
Pfizer
Phase 3
954
Suita, Chuo-ku, Shinjuku-ku
2026-06-10
Recruiting
argenx
Phase 3
230
Okayama, Bunkyō-Ku, Ōta-ku, Iizuka, Kawasaki, Kitakyushu, Kyoto, Nagasaki
2026-06-10
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 3
20
Fukuoka
2026-06-10
Active, closed
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
NCT07468071Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
DrugsTNO155·Opnurasib·Trametinib·Cetuximab
Novartis Pharmaceuticals
Phase 1/2
25
Kashiwa, Koto Ku
2026-06-08
Recruiting
Asan Medical Center
Phase 4
1,058
Osaka
2026-06-05
Recruiting
Takeda
Phase 2
92
Fukuoka, Kumamoto, Isahaya-shi, Yodogawa-ku, Osaka-shi, Shinjuku-ku
2026-06-04
Recruiting
Boehringer Ingelheim
Phase 2
60
Osaka, Sakai, Tokyo, Chuo-ku
2026-06-04
Recruiting
GlaxoSmithKline
Phase 3
600
Aichi, Fukuoka, Hokkaido, Hyōgo, Kanagawa, Kyoto, Mie, Numakunai
2026-06-04
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Nagoya, Gifu, Bunkyo Ku, Kodaira, Yonago
2026-06-03
Recruiting
Novartis Pharmaceuticals
Phase 1
63
Fukuoka
2026-06-02
Recruiting
Dompé Farmaceutici S.p.A
Phase 3
150
Tōon, Bunkyō City
2026-06-02
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 1
120
Fukuoka
2026-06-02
Recruiting
University of Shizuoka
Phase 1
58
Sumida-ku
2026-06-01
Recruiting
Efficacy of pHA130 Hemoadsorption on Protein-Bound Uremic Toxins and Quality of Life in Kidney Failure
NCT07656168ESRD (End-Stage Renal Disease), Maintenance Hemodialysis
China-Japan Friendship Hospital
Not applicable
100
2026-06-01
Recruiting
A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia
NCT07604064Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid Leukemia
DrugOlutasidenib
Kissei Pharmaceutical Co., Ltd.
Phase 2
3
Tokyo and Other Japanese Cities
2026-06
Not yet open
Matthias Stuber
Observational
300
Tsu
2026-06
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Chiba, Fukuoka, Gunma, Kamakura-shi, Kyoto, Matsuyama, Okayama, Sapporo
2026-05-31
Recruiting
Pfizer
Phase 3
3,230
Toyota-shi, Fukui-shi, Fukuoka, Kasuga, Sapporo, Hioki, Osaka, Bunkyo
2026-05-29
Recruiting
Pfizer
Phase 2
24
Saitama-shi, Kumamoto, Tokyo
2026-05-28
Recruiting
AbbVie
Phase 1
30
Nagoya, Bunkyo-ku, Shinjuku-ku
2026-05-28
Recruiting
Novartis Pharmaceuticals
Phase 1
194
Hirakata
2026-05-28
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Eli Lilly and Company
Phase 1
215
Chiba, Okayama, Tokyo
2026-05-28
Recruiting
Amgen
Phase 3
304
Nagoya, Meguro-ku, Ube, Tokyo
2026-05-27
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Toyoake, Kamogawa, Sapporo, Kobe, Shiwa-Gun, Tsu, Kurashiki, Bunkyo Ku
2026-05-27
Recruiting
UCB Biopharma SRL
Phase 3
120
Kobe, Minatoku, Sendai
2026-05-27
Recruiting
Pemafibrate for Symptomatic ICAS RCT
NCT07562178Intracranial Atherosclerotic Disease (ICAD), Hypertriglyceridaemia, Stroke (CVA) or TIA
DrugPemafibrate
Tokyo Women's Medical University
Not applicable
270
Toyoake, Yachiyo, Yoshida, Fukuyama, Hiroshima, Kobe, Tsukuba, Hizume
2026-05-26
Recruiting
Novartis Pharmaceuticals
Phase 1
208
Hirakata
2026-05-25
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 3
250
Nagasaki, Osaka, Tokyo
2026-05-25
Recruiting
Janssen Research & Development, LLC
Phase 3
644
Bunkyō City, Hamamatsu, Higashiharima, Kagoshima, Kashiwa, Kumamoto, Minatoku, Mitaka
2026-05-23
Recruiting
Yanbing Yu
Not applicable
142
2026-05-23
Recruiting
BeOne Medicines
Phase 3
1,056
Kurumeshi, Otashi, Hiroshima, Sapporo, Nishinomiyashi, Kagoshima, Iseharashi, Kawasakishi
2026-05-22
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Bunkyō City, Hamamatsu, Hirosaki, Kagoshima, Kashiwa, Kobe, Kumamoto, Minatoku
2026-05-22
Recruiting
Eli Lilly and Company
Phase 3
550
Chūōku, Hachiōji, Ōbu, Shinjuku, Shinjyuku, tabashi City
2026-05-22
Active, closed
Kite, A Gilead Company
Phase 3
550
Tokyo
2026-05-22
Recruiting
AbbVie
Phase 3
990
Kashiwa-shi, Matsuyama, Kobe, Kawasaki-shi, Osaka, Koto-ku
2026-05-22
Recruiting
Takeda
Phase 3
300
Nagoya, Fukushima, Gifu, Fukuyama-shi, Amagasaki-shi, Mibu, Bunkyo-ku, Shinagawa-ku
2026-05-21
Recruiting
Regeneron Pharmaceuticals
Phase 3
270
Nagoya, Okayama, Tokushima, Kofu, Matsumoto-shi
2026-05-21
Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
DrugDonanemab
Eli Lilly and Company
Phase 2
350
Bunkyō City, Fujisawa, Himeji, Inage, Kawasaki, Kobe, Kōtoku, Kurashiki
2026-05-20
Recruiting
Gang Hou
Not applicable
110
2026-05-20
Recruiting
China-Japan Friendship Hospital
Not applicable
80
2026-05-18
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
340
Bunkyo, Minato
2026-05-18
Recruiting
Takeda
Phase 2
222
Fukuoka, Nagano, Izumisano, Osaka
2026-05-17
Recruiting
Exercise Training After Upper Gastrointestinal Cancer Surgery
NCT07561840Esophageal Cancer, Gastric Cancer (Diagnosis), Upper Gastrointestinal Cancer
Kansai Medical University
Not applicable
171
Hirakata
2026-05-15
Recruiting
Hoffmann-La Roche
Phase 3
138
Kashihara-shi, Shinjuku-Ku
2026-05-15
Recruiting
FFR-Guided Revascularization in Atherosclerotic Renal Artery Stenosis
NCT07511309Atherosclerotic Renal Artery Stenosis, Fractional Flow Reserve, Optimal Medical Therapy, Stent Implantation
Chinese Academy of Medical Sciences, Fuwai Hospital
Not applicable
300
2026-05-15
Recruiting
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
NCT07392892Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
DrugsPF-08634404·Nivolumab
Pfizer
Phase 2/3
840
Nagoya
2026-05-14
Recruiting
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
NCT07486934Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy, Steinert Disease
DrugZeleciment basivarsen
Dyne Therapeutics
Phase 3
150
Kashiwazaki, Suita-shi, Toyonaka-Shi, Kodaira, Ube-Shi
2026-05-14
Recruiting
Ipsen
Phase 3
350
Chiba, Hiroshima, tabashi City, Yokohama, Ōmura, Kashihara, Niigata, Suita
2026-05-14
Recruiting
Novartis Pharmaceuticals
Observational
10
Kobe, Ushiku, Kanoya, Yokohama, Osaka
2026-05-13
Recruiting
A Clinical Study of TS-172 in Hyperphosphatemia Patients on Peritoneal Dialysis
NCT07548853Hyperphosphatemia Patients on Peritoneal Dialysis
DrugTS-172 20~
Taisho Pharmaceutical Co., Ltd.
Phase 3
30
Tokyo
2026-05-13
Recruiting
Novartis Pharmaceuticals
Observational
395
Tokyo
2026-05-11
Recruiting
Incyte Corporation
Phase 1
218
Kashiwa Chiba, Toon, Ehime
2026-05-11
Recruiting
Genmab
Phase 2
160
Kashiwa, Yokohama, Suita, Kōtoku
2026-05-11
Active, closed
Novartis Pharmaceuticals
Phase 3
5,700
Nagoya, Seto, Hirosaki, Asahi, Funabashi, Matsudo, Kitakyushu, Ōgaki
2026-05-11
Recruiting
Juntendo University
Phase 4
550
Handa, Nagoya, Ōbu, Toyota, Tōon, Fukuoka, Iizuka, Maebashi
2026-05-11
Recruiting
Novo Nordisk A/S
Phase 3
5,610
Uwajima-shi, Bunkyo-ku, Tokyo, Chiba-shi,Chiba, Chikushino-shi, Fukuoka, Fuchu-shi,Tokyo, Fukuoka-shi, Fukuoka, Higashiosaka-shi, Osaka, Himeji-shi, Hyogo
2026-05-11
Not yet open
Nanjing IASO Biotechnology Co., Ltd.
Phase 1/2
17
Bunkyo-ku, Shibuya-ku, tabashi City
2026-05-10
Active, closed
A Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
NCT07548840Hyperphosphatemia Patients on Hemodialysis
DrugTS-172 20~
Taisho Pharmaceutical Co., Ltd.
Phase 3
34
Tokyo
2026-05-08
Recruiting
Novartis Pharmaceuticals
Phase 2
323
Suita, Chuo Ku, Chuo-ku, Shinjuku Ku
2026-05-07
Recruiting
Eli Lilly and Company
Phase 2
531
Chūōku, Fujiidera, Isehara, Kobe, Kumamoto, Sapporo, Shinjuku-Ku
2026-05-06
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 3
1,020
Nagoya, Fukuoka, Yokohama, Sakai-shi, Kitaadachi-gun, Sunto, Chūōku, Kōtoku
2026-05-06
Recruiting
Mirati Therapeutics Inc.
Phase 2
170
Tōon
2026-05-06
Recruiting
Novo Nordisk A/S
Phase 3
300
Fukuoka, Hiroshima, Kumamoto, Okinawa, Osaka, Sapporo-shi, Hokkaido, Shizuoka, Tokyo
2026-05-05
Recruiting
AstraZeneca
Phase 3
670
Chiba, Chūōku, Fukuoka, Hamamatsu, Kamakura-shi, Kanazawa, Kashiwa, Kobe
2026-05-04
Recruiting
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
NCT07488676Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
DrugXNW27011
Astellas Pharma Global Development, Inc.
Phase 1/2
150
Kashiwa-shi, Chuo-ku, Koto-ku
2026-05-04
Recruiting
Merck Sharp & Dohme LLC
Phase 3
876
Kitakyushu, Fukushima, Yamagata
2026-05-04
Recruiting
Boehringer Ingelheim
Phase 1
60
Chiba, Kashiwa, Tokyo, Chuo-ku
2026-05-01
Not yet open
China-Japan Union Hospital
Not applicable
220
2026-05-01
Recruiting
China-Japan Friendship Hospital
Not applicable
200
2026-05-01
Not yet open
Kunming Pharmaceuticals, Inc.
Phase 2
100
2026-04-30
Not yet open
Covered vs Bare Metal Stents for Atherosclerotic Renal Artery Stenosis
NCT07566065Atherosclerotic Renal Artery Stenosis, Hypertension, Renal Artery Stenosis
Chinese Academy of Medical Sciences, Fuwai Hospital
Not applicable
150
2026-04-30
Recruiting
AbbVie
Phase 2/3
900
Koto-ku
2026-04-30
Recruiting
Eli Lilly and Company
Phase 2
342
Chūōku, Isehara, Kobe, Sapporo, Shinjuku-Ku
2026-04-29
Recruiting
Rohto Pharmaceutical Co., Ltd.
Phase 2
50
Osaka
2026-04-28
Recruiting
Biogen
Phase 3
30
Tokyo
2026-04-28
Recruiting
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
NCT07354074Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
DrugsAsciminib single agent·ABL001
Novartis Pharmaceuticals
Phase 2
50
Yokohama, Fukuoka, Saitama
2026-04-28
Active, closed
Pfizer
Observational
1
Tokyo
2026-04-27
Recruiting
Hoffmann-La Roche
Phase 3
360
Nagoya, Maebashi, Kashihara-shi, Suginami-Ku
2026-04-27
Recruiting
MDT-0123 Japan Study
NCT07414745Disc Degeneration, Spinal Deformity
Medtronic Spinal and Biologics
Phase 3
140
Kobe, Isehara, Higashiosaka, Koshigaya, Hamamatsu, Adachi-Ku, Minato-Ku, Nakano-Ku
2026-04-24
Recruiting
Gang Hou
Phase 1/2
105
2026-04-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
590
Nagoya, Hirosaki, Tōon, Sapporo, Kobe, Tsukuba, Kita-gun, Kawasaki
2026-04-23
Recruiting
Kyowa Kirin Co., Ltd.
Phase 2
6
Chiba, Gifu, Hyōgo, Ibaraki, Kagoshima, Kanagawa, Kyoto, Miyagi
2026-04-23
Recruiting
Takeda
Phase 2
42
Tokyo, Fukui, Hiroshima, Kanagawa, Fukuoka, Hyōgo, Yamanashi, Ehime
2026-04-22
Not yet open
Ongericimab Injection Reducing Recurrence of Ischemic Stroke
NCT07242599Ischemic Cerebral Infarction
Beijing Tiantan Hospital
Phase 3
4,810
2026-04-22
Recruiting
Alkermes, Inc.
Phase 3
176
Kitakyushu-shi, Osaka, Shibuya-ku, Shinjuku-ku, Kumamoto, Tokyo
2026-04-22
Recruiting
Boehringer Ingelheim
Phase 2
405
Aichi, Nagoya, Chiba, Chiba, Chiba, Urayasu, Fukuoka, Kitakyushu, Hokkaido, Sapporo, Miyagi, Sendai, Miyazaki, Miyazaki, Nagano, Matsumoto
2026-04-20
Recruiting
BioMarin Pharmaceutical
Phase 2/3
160
Hokkaido, Osaka, Tokyo
2026-04-20
Active, closed
Pfizer
Observational
59
Tokyo
2026-04-20
Recruiting
Novo Nordisk A/S
Phase 2
270
Chiba-shi, Chiba, Ibaraki, Soka-shi, Saitama, Tokyo
2026-04-17
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
DrugRituximab
Eli Lilly and Company
Phase 1
460
Chiba, Okayama, Tokyo
2026-04-17
Recruiting
GlaxoSmithKline
Phase 2
200
Aichi, Chiba, Ehime, Fukushima, Gunma, Hokkaido, Ishikawa, Numakunai
2026-04-15
Recruiting
Aichi Medical University
Not applicable
90
Aichi, Gifu
2026-04-15
Recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
752
2026-04-15
Active, closed
Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
NCT07340138Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 1
3
Kamogawa, Sapporo, Chūō
2026-04-15
Recruiting
A Study of GEN1106 in Participants With Solid Tumors
NCT07416123Solid Tumors, Urothelial Carcinoma
Genmab
Phase 1
103
Chuo Ku
2026-04-14
Recruiting
Femoral Triangle Block vs Adductor Canal Block on Early Quadriceps Function After Total Knee Arthroplasty
NCT07524387Total Knee Arthroplasty, Total Knee Arthroplasty Recovery, Total Knee Arthroplasty Postoperative Pain
Social Medical Corporation Daiyukai
Not applicable
136
Ichinomiya
2026-04-13
Recruiting
Boehringer Ingelheim
Phase 3
670
Aichi, Toyoake, Aomori, Hirosaki, Fukuoka, Fukuoka, Hokkaido, Sapporo, Kagoshima, Kagoshima, Miyagi, Sendai, Osaka, Sakai, Saitama, Hidaka
2026-04-13
Not yet open
Effect of tNGS on CAP Patients With Initial Treatment Failure
NCT07472114Community Acquired Pneumonia (CAP)
Capital Medical University
Not applicable
524
2026-04-10
Recruiting
Aesculap AG
Observational
178
Fukuoka, Okayama, Kyoto, Osaka-Fu, Osaka
2026-04-10
Recruiting
Incyte Corporation
Phase 3
588
Akashi, HYGO, Fukuoka Fukuoka, Kahoku-gun, Kitaadachi-gun, Kōtoku, Mitaka-shi, Osaka, Sapporo Hokkaido
2026-04-09
Recruiting
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
NCT07403721Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Amgen
Phase 1
464
Nagoya, Kashiwa-shi, Chuo-ku, Koto-ku
2026-04-08
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
400
Chikugo, Sapporo, Zentsujichó, Miyakonojō, Bunkyo-ku, Ōta-ku, Yokohama, Kanagawa
2026-04-07
Recruiting
Alkermes, Inc.
Phase 3
150
Kitakyushu-shi, Osaka, Shibuya-ku, Shinjuku-Ku, Kumamoto
2026-04-06
Recruiting
Astellas Pharma Inc
Phase 1/2
84
Sendai, Bunkyo-ku, Toyama, Kyoto, Tokushima
2026-04-03
Recruiting
Genmab
Phase 3
544
Sapporo, Akashi, Tsu, Takatsuki, Hidaka, Kashiwa, Kawasaki, Kurume
2026-04-03
Recruiting
Sanofi
Observational
2,500
Kitakyushu-Shi, Takamatsu, Saga, Bunkyo-ku, tabashi City, Niigata
2026-04-01
Not yet open
Nanjing Reju Therapeutics Co., Ltd
Phase 1
42
2026-04
Not yet open
China-Japan Friendship Hospital
Not applicable
285
2026-04
Recruiting
Propel Drug-Eluting Sinus Implant Family IBUKI Cohort
NCT07546682Chronic Rhinosinusitis (CRS)
Medtronic
Observational
100
Asahikawa
2026-04
Not yet open
China-Japan Friendship Hospital
Not applicable
420
2026-04
Recruiting
Eisai Co., Ltd.
Phase 2
256
Nagoya, Toyoake, Kitakyushu, Sapporo, Kobe, Nishinomiya, Sendai, Naha
2026-03-31
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
60
Nagoya, Yokohama, Chūō
2026-03-27
Recruiting
TAMBE Japan Post-Marketing Surveillance
NCT07147569Thoracoabdominal Aortic Aneurysm, Pararenal Aortic Aneurysm
W.L.Gore & Associates
Observational
100
Minatoku, Nagoya, Osaka, Suita
2026-03-27
Recruiting
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 2
20
Chūōku, Fukuoka, Kanazawa, Nagoya
2026-03-26
Active, closed
Intuitive Surgical
Observational
625
Ichinomiya, Toyoake, Yokohama, Kyoto, Tsu, Ageo, Tokyo
2026-03-26
Recruiting
Bristol-Myers Squibb
Phase 1/2
474
Kobe, Shiwa-gun Yahaba-cho, Koto-ku, Toyoma, Fukuoka, Niigata
2026-03-26
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Asahikawa, Bunkyō City, Fujiidera, Fukuoka, Hirosaki, Kagoshima, Kashiwa, Mitaka
2026-03-26
Recruiting
Eisai Inc.
Phase 2
64
Sapporo, Yokohama, Kumamuto-shi, Oskaka
2026-03-26
Recruiting
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
NCT07146906Immunoglobulin A Nephropathy (IgAN)
DrugZigakibart
Novartis Pharmaceuticals
Phase 2
32
Kawasaki, Miyazaki
2026-03-26
Recruiting
Bristol-Myers Squibb
Phase 3
325
Suita, Nankoku-shi, Osaka
2026-03-25
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Sagamihara, Kashihara, Bunkyo Ku
2026-03-24
Recruiting
Shandong Suncadia Medicine Co., Ltd.
Phase 1
168
2026-03-24
Recruiting
Hoffmann-La Roche
Phase 3
1,600
Aichi, Fukuoka, Hokkaido, Osaka, Tokyo
2026-03-23
Recruiting
Merck Sharp & Dohme LLC
Phase 3
450
Minato, Fukuoka, Tokushima
2026-03-23
Recruiting
Amgen
Phase 3
406
Tomakomai-shi, Osaka, Chuo-shi
2026-03-23
Recruiting
Novartis Pharmaceuticals
Observational
30
Kurume, Osaka, Suita, Bunkyo Ku
2026-03-23
Recruiting
Boehringer Ingelheim
Phase 2
132
Aichi, Kasugai, Aichi, Nagoya, Fukuoka, Fukuoka, Hyogo, Kobe, Tokyo, Minato-ku, Tokyo, Shinjuku-ku
2026-03-23
Recruiting
GlaxoSmithKline
Phase 1
97
Saitama, Shizuoka, Tokyo
2026-03-23
Not yet open
Dermavon Holdings Limited
Phase 2
160
2026-03-20
Recruiting
AO Foundation, AO Spine
Observational
648
Tochigi
2026-03-19
Recruiting
Amgen
Phase 3
71
Okayama
2026-03-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
400
Hirosaki, Kitakyushu, Fukushima, Osaka, Yamagata
2026-03-18
Active, closed
AbbVie
Phase 2
14
Nagoya, Yoshida-gun, Fukuoka, Maebashi, Hiroshima, Higashiibaraki-gun, Kyoto, Sakai-shi
2026-03-17
Recruiting
AstraZeneca
Phase 1/2
180
Chūōku, Kashiwa
2026-03-17
Recruiting
Hoffmann-La Roche
Phase 3
2,000
Aichi, Fukuoka, Hokkaido, Osaka, Tokyo
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 1/2
198
Osakasayama-shi, Kashiwa
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 3
850
Nagoya, Kobe, Nishinomiya, Sagamihara, Yokohama, Sendai, Hirakata, Sakai
2026-03-16
Recruiting
BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System
NCT07118358Leadless Pacemaker, Bradycardia, AV Block, Cardiac Rhythm Disorder
Biotronik, Inc.
Not applicable
325
Kitakyushu, Suita
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 2/3
690
Nagoya, Chiba, Kashiwa, Matsuyama, Yokohama, Kurashiki, Osaka, Suita
2026-03-13
Recruiting
Bristol-Myers Squibb
Phase 3
750
Toyohashi, Funabashi, Tōon, Sapporo, Nishinomiya, Kanazawa, Kamakura, Yokohama
2026-03-12
Recruiting
Astellas Pharma Global Development, Inc.
Phase 2
240
Gifu, Kobe, Tsukuba, Kawasaki, Bunkyo-ku, Koto-ku, Ube, Kyoto
2026-03-12
Recruiting
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
NCT07457918Common Warts (Verruca Vulgaris), Common Warts, Human Papilloma Virus (HPV), Warts
Verrica Pharmaceuticals Inc.
Phase 3
250
Kumamoto, Tokyo
2026-03-11
Recruiting
Pfizer
Phase 1/2
132
Shinjuku-ku, Fukuoka, Yamagata
2026-03-11
Recruiting
Takeda
Phase 3
1,182
Minami-ku, Nagoya-shi, Nagoya, Fukuoka, Tsu, Mie, Sasebo-shi, Osaka, Chuo-ku, Meguro-Ku
2026-03-11
Recruiting
Tatsuhiro Hisatsune
Not applicable
300
Kashiwa
2026-03-10
Active, closed
Ipsen
Phase 1
6
Kanagawa, Kobe, Kyoto, Osaka, Tokyo
2026-03-10
Recruiting
Phase II Trial of RC1416 Injection in Asthma
NCT07403487Moderate to Severe Asthma
DrugRC1416
Nanjing RegeneCore Biotech Co., Ltd.
Phase 2
195
2026-03-10
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
NCT07332481Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
DrugEnpatoran
EMD Serono Research & Development Institute, Inc.
Phase 3
202
Nagoya, Chiba, Kitakyushu-shi, Fukushima, Asahikawa-shi, Sapporo, Kobe, Kanazawa
2026-03-10
Recruiting
Novartis Pharmaceuticals
Phase 2
272
Amagasaki, Kobe, Bunkyo Ku, Chiyoda-ku
2026-03-09
Recruiting
Eli Lilly and Company
Phase 4
150
Isehara
2026-03-09
Recruiting
Novartis Pharmaceuticals
Phase 2
210
Nagoya, Urayasu, Shinjuku Ku, Kofu, Niigata
2026-03-09
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
DrugsCetuximab·Nab-paclitaxel·Gemcitabine
Revolution Medicines, Inc.
Phase 3
900
Kashiwa, Koto-Ku, Chiba, Fukuoka, Kanagawa, Osaka, Tokyo, Wakayama
2026-03-09
Recruiting
Regeneron Pharmaceuticals
Phase 3
1,120
Tōon, Ōta, Akashi, Kita-gun, Isehara-Shi, Kyoto, Sendai, Chuo
2026-03-09
Recruiting
AusperBio Therapeutics Inc.
Phase 2
84
Musashino, Shinjuku-Ku
2026-03-06
Recruiting
Incyte Corporation
Phase 3
700
Akashi-shi, Chiba, Chūōku, Fukuoka, Hidaka-shi, Kashiwa-shi, Kawasaki-shi, Kita-gun
2026-03-05
Recruiting
Bristol-Myers Squibb
Observational
200
Minato-ku, Chiba
2026-03-05
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Aichi, Bunkyō City, Chiba, Chūō, Fuchū, Fukuoka, Fukushima, Isehara
2026-03-05
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 4
75
Ibaraki, Kitakyushu-shi, Kumamoto
2026-03-04
Recruiting
Shanghai Ark Biopharmaceutical Co., Ltd.
Phase 2/3
290
2026-03-03
Recruiting
TriClip Japan Post-Approval Study
NCT07509658Tricuspid Regurgitation
Abbott Medical Devices
Observational
250
Suita
2026-03-02
Active, closed
China-Japan Friendship Hospital
Not applicable
469
2026-03-01
Recruiting
Acute Ischemic Stroke in Patients With Active Cancer
NCT07819526Acute Ischemic Stroke, Active Cancer
Osaka University
Observational
500
Suita
2026-03-01
Recruiting
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
875
Bunkyō City, Chūōku, Maebashi, Nagasaki, Nagoya, Okayama, Tokushima, Yamagata
2026-03-01
Recruiting
AbbVie
Phase 1
127
Bunkyo Ku, Koto-ku
2026-02-27
Recruiting
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
NCT07306559Advanced Relapsed or Refractory Germ Cell Tumours, Advanced Relapsed or Refractory Endometrial Cancer, Advanced Relapsed or Refractory Ovarian Cancer
Boehringer Ingelheim
Phase 1
187
Chiba, Kashiwa, Tokyo, Koto-ku
2026-02-27
Recruiting
AstraZeneca
Phase 3
508
Bunkyō City, Kashiwa, Kyoto, Nagoya, Shibuya-ku, Shinjuku-ku
2026-02-23
Recruiting
Asian Gynecological Brachytherapy Registry in Cervical Cancer
NCT07196033Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IVA Cervical Cancer FIGO 2018, Stage IB Cervical Cancer FIGO 2018
Tata Memorial Hospital
Observational
1,000
Maebashi, Tokyo
2026-02-20
Recruiting
A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
NCT07363590Systemic Lupus Erythematosus, Rheumatoid Arthritis
DrugMK-1045
Merck Sharp & Dohme LLC
Phase 1
21
Bunkyo, Shinjyuku
2026-02-19
Recruiting
Takeda
Observational
13
Tokyo
2026-02-19
Active, closed
Ipsen
Phase 3
1,300
Chiyoda-ku, Chūōku, Fukuoka, Minatoku, Nerima-ku, Sakaishi, Sapporo, Takatsuki-shi
2026-02-18
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
614
Kashiwa, Matsuyama, Fukuoka, Kashihara-shi, Sakai, Suita, Bunkyo-ku, Koto
2026-02-17
Recruiting
Boehringer Ingelheim
Phase 3
286
Aichi, Kasugai, Aichi, Nagoya, Chiba, Chiba, Fukuoka, Fukuoka, Fukuoka, Kurume, Hyogo, Kobe, Kanagawa, Yokohama, Nara, Nara
2026-02-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
900
Nagoya, Kurume, Ōta, Sapporo, Akashi, Shiwa-gun, Hidaka, Sunto-gun,
2026-02-16
Not yet open
Evidence-Based Nursing to Reduce Adverse Events Regarding Ventilator Associated Pneumonia, Pressure Injuries and Central Line Bloodstream Infection in Intensive Care Unit in Bangladesh
NCT07299799Ventilator Acquired Pneumonia, Central Line Associated Blood Stream Infections (CLABSI), Pressure Ulcer (PU), Medical Device Related Pressure Ulcer (MDRPU)
Hiroshima University
Not applicable
272
Hiroshima
2026-02-15
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 1
138
Tokyo
2026-02-13
Recruiting
I-Mab Biopharma US Limited
Phase 2
180
Kashiwa, Tokyo
2026-02-11
Recruiting
ViiV Healthcare
Phase 2
186
Fukuoka, Kanagawa, Okinawa, Osaka, Tokyo
2026-02-11
Recruiting
Pfizer
Phase 2/3
1,156
Nagoya, Fukuoka, Iizuka-shi, Hiroshima, Kure, Ginowan, Sakai, Fujieda
2026-02-11
Recruiting
GlaxoSmithKline
Phase 1
44
Fukuoka, Hiroshima, Hokkaido
2026-02-10
Recruiting
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
NCT07201922Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
80
Aichi, Seto, Fukushima, Koriyama, Kanagawa, Yokohama, Osaka, Sakai, Shizuoka, Hamamatsu, Tokyo, Shinjuku-ku
2026-02-10
Recruiting
Eli Lilly and Company
Phase 2
450
Chikugo, Fukushima, Hachinohe, Hiratsuka, Karatsu, Kodaira, Kumamoto, Kurume
2026-02-10
Recruiting
GlaxoSmithKline
Phase 1/2
54
Tokyo
2026-02-10
Recruiting
Pfizer
Phase 1/2
224
Yokohama, Suita, Shinjuku-ku, Fukuoka, Yamagata
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
900
Chūōku, Izumisano, Kawasaki, Kisarazu, Kure, Kyoto, Matsuyama, Osaka
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
800
Bunkyō City, Fukuoka, Kitahiroshima, Kitakyushu, Minatoku, Osaka, Sapporo, Shibuya-ku
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
1,000
Arakawa City, Chikugo, Chiyoda City, Fukuoka, Fukushima, Ginowan, Hiratsuka, Karatsu
2026-02-09
Recruiting
Eli Lilly and Company
Phase 3
900
Chiba, Chūōku, Kitakyushu-Shi, Miyazaki, Nagareyama, Ōita, Saitama, Sashima
2026-02-09
Recruiting
MSA-01 in Multiple System Atrophy
NCT07446894Multiple System Atrophy (MSA)
Tokyo University
Phase 3
140
Nagoya, Chiba, Fukuoka, Sapporo, Kagoshima, Kyoto, Okayama, Hasuda
2026-02-09
Active, closed
Janssen Research & Development, LLC
Phase 2
168
Gunma, Okayama
2026-02-08
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
120
2026-02-06
Recruiting
Eli Lilly and Company
Phase 3
1,980
Adachi-ku, Chūōku, Fukuoka, Minato, Mitaka, Suita-shi, Tokyo
2026-02-06
Recruiting
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3
266
Akita, Chiba, Maebashi, Sapporo, Kobe, Sagamihara-shi, Kochi, Nagano
2026-02-05
Recruiting
Eli Lilly and Company
Phase 3
300
Ichikawa, Iruma, Moriyama, Osaka, Sendai, Shizuoka
2026-02-05
Recruiting
Bristol-Myers Squibb
Observational
36
Minato-ku
2026-02-05
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1/2
428
Kashiwa-shi, Hirakata-shi, Chuo-ku, Koto-ku
2026-02-05
Recruiting
Janssen Research & Development, LLC
Phase 3
400
Bunkyō City, Chiba, Kamakura-shi, Kamogawa, Kofu, Minato, Shibuya City, Yokohama
2026-02-04
Recruiting
Eli Lilly and Company
Phase 1
68
Shinjuku-ku
2026-02-04
Recruiting
Pancreatic Cancer Screening Using the Enzeavour Assay in Japan
NCT07605819Pancreatic Cancer, Pancreatic Neoplasms
Cosomil, Inc.
Not applicable
10,000
Nagakute, Nagoya, Chiba, Fukuoka, Kasamatsuchō, Hiroshima, Onomichi, Obihiro
2026-02-04
Recruiting
AstraZeneca
Phase 3
2,130
Bunkyō City, Chūōku, Hirakata-shi, Hiroshima, Kashiwa, Kitaadachi-gun, Kōtoku, Kurashiki-shi
2026-02-03
Recruiting
Bristol-Myers Squibb
Phase 1/2
240
Hirakata, Chuo-ku
2026-02-03
Recruiting
Alnylam Pharmaceuticals
Phase 3
125
Bunkyo C, Kumamoto, Matsumoto-shi, Suita
2026-02-03
Recruiting
Rabin Medical Center
Phase 3
254
Izumi-Shi, Nara, Osaka, Setagaya-Ku
2026-02-01
Recruiting
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
DrugsSigvotatug vedotin·PF-08634404
Pfizer
Phase 1/2
162
Kashiwa, Sendai, Hirakata, Nagaizumi-cho, Bunkyo-ku
2026-01-30
Recruiting
Genmab
Phase 2
240
Sagamihara, Yokohama, Kyoto, Nagoya, Saitama, Sakai, Chūō, Tokyo
2026-01-30
Recruiting
Bristol-Myers Squibb
Observational
150
Chiba, Kashiwa-shi, Sakura, Matsuyama, Chikushino-shi, Fukuoka, Asahikawa, Sapporo
2026-01-29
Recruiting
Bristol-Myers Squibb
Phase 3
166
Chikugo-Shi, Sapporo, Zentsujichó, Miyakonojō, Bunkyo-ku, Ōta-ku, Yokohama, Kanagawa
2026-01-29
Recruiting
Tokyo Women's Medical University
Phase 3
950
Akita, Chiba, Fukuoka, Fukushima, Fukuyama, Hamamatsu, Hirakata, Hiroshima
2026-01-28
Active, closed
AstraZeneca
Phase 1/2
6
Kashiwa
2026-01-27
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 1
45
Hiroshima, Kashiwa, Nagoya, Shizuoka, Tokyo
2026-01-26
Recruiting
AbbVie
Phase 2
165
Sakai-shi
2026-01-23
Recruiting
TheraSphere Japan Pre-Market Study
NCT07377487Liver Neoplasms
Boston Scientific Corporation
Not applicable
51
Nishinomiya, Kanazawa, Kashihara, Sayama, Chuo Ku
2026-01-22
Recruiting
Sanofi
Phase 3
751
Kamakura, Nishinomiya, Tsu
2026-01-22
Recruiting
Generate Biomedicines
Phase 3
786
Seto-shi, Matsuyama, Fukui-shi, Iizuka-Shi, Isesaki-Shi, Hiroshima, Asahikawa-shi, Himeji
2026-01-20
Active, closed
Janssen Research & Development, LLC
Phase 2
189
Matsudo, Nishiku, Sakai, tabashi City, Tachikawa, Yokohama
2026-01-20
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,023
Nagoya, Tōon, Kurume, Ōta, Sapporo, Akashi, Shiwa-gun, Yokohama
2026-01-19
Recruiting
China-Japan Friendship Hospital
Observational
790
2026-01-19
Recruiting
China-Japan Friendship Hospital
Observational
210
2026-01-19
Recruiting
Endocardial Delivery for Myocardial Regeneration Using Allogeneic iPSC-derived Cardiomyocyte Spheroids for HF With Systolic Dysfunction (EMERALD Study)
NCT07347197Heart Failure, Ischemic Heart Failure, Ischemic Heart Disease, Dilated Cardiomyopathy (DCM)
Heartseed Inc.
Phase 1/2
14
Tsukuba, Kawasaki, Matsumoto, Shinagawa-Ku, Shinjuku-ku
2026-01-19
Recruiting
Sanofi
Phase 3
751
Bunkyō City, Chikushino-shi, Hachiōji, Kagoshima, Kamakura, Kashiwa, Kobe, Kōriyama
2026-01-16
Recruiting
Boehringer Ingelheim
Phase 3
400
Aichi, Nagoya, Aichi, Toyoake, Chiba, Kashiwa, Fukuoka, Fukuoka, Fukuoka, Kitakyushu, Hiroshima, Hiroshima, Hokkaido, Sapporo, Kanagawa, Sagamihara
2026-01-16
Recruiting
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
NCT07220616Hematological Malignancies, B-cell Non-Hodgkin Lymphoma
Daiichi Sankyo
Phase 1/2
420
Nagoya, Tokyo
2026-01-16
Active, closed
Janssen Research & Development, LLC
Phase 2
157
Fuchū, Kagoshima, Kitakyushu-shi, Osaka, Sanuki, Shimonoseki
2026-01-15
Recruiting
Sanofi
Phase 3
160
Kōriyama, Sapporo, Yahaba, Higashi-Matsuyama, Kodaira, Kyoto, Tokyo
2026-01-14
Recruiting
Takeda
Observational
50
Tokyo
2026-01-13
Recruiting
Eli Lilly and Company
Phase 3
150
Abeno, Iruma, Kawasaki, Kofu, Kōriyama, Kumamoto, Nagano, Naka
2026-01-12
Not yet open
China-Japan Friendship Hospital
Early Phase 1
60
2026-01-10
Not yet open
Nagoya City University
Phase 2
30
Nagoya
2026-01-10
Recruiting
Alnylam Pharmaceuticals
Observational
2,000
Bunkyō City, Kumamoto, Kurume, Matsumoto, Sendai, Shinjuku, Suita, Tsukuba
2026-01-09
Recruiting
Taisho Pharmaceutical Co., Ltd.
Phase 3
100
Tokyo
2026-01-09
Recruiting
AstraZeneca
Phase 1/2
85
Bunkyō City, Kashiwa, Okayama
2026-01-09
Recruiting
Amicus Therapeutics
Phase 3
8
Sagamihara
2026-01-08
Recruiting
AbbVie
Phase 2/3
680
Nagoya, Matsuyama, Kurume-shi, Isehara, Kyoto
2026-01-08
Recruiting
Insmed Incorporated
Phase 3
344
Nagakute, Seto, Hirosaki, Narashino-shi, Narita-shi, Sapporo, Yokohama, Kyotoshi
2026-01-07
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Nagoya, Chiba, Matsuyama, Kurume, Otashi, Asahikawa, Sapporo, Kobe
2026-01-06
Recruiting
Takara Bio Inc.
Phase 3
5
Osaka, Fukuoka, Kashiwa
2026-01-05
Recruiting
Amgen
Phase 2
14
Sapporo
2026-01-02
Recruiting
Bristol-Myers Squibb
Phase 2/3
590
Nagoya, Kashiwa, Otashi, Sapporo, Himeji, Kobe, Shiwa-gun Yahaba-cho, Kawasaki
2026-01-02
Recruiting
Acepodia Biotech, Inc.
Phase 1/2
34
Kahoku-gun
2026-01-01
Recruiting
A Phase I Trial of Af-001 in Patients With Differentiated Thyroid Cancer
NCT07287748DTC - Differentiated Thyroid Cancer
Alpha Fusion Inc.
Phase 1
38
Kashiwa
2026-01-01
Not yet open
China-Japan Friendship Hospital
Observational
284
2026-01-01
Not yet open
Kumamoto University
Not applicable
60
Kumamoto
2026-01
Recruiting
Bristol-Myers Squibb
Phase 2/3
990
Nagoya, Toyoake, Chiba, Kashiwa, Matsuyama, Sapporo, Kobe, Yokohama
2025-12-31
Recruiting
Robotic Gastrectomy With 5th Arm
NCT07310888Stomach Cancer
Chinese University of Hong Kong
Not applicable
10
Nagoya
2025-12-31
Recruiting
AstraZeneca
Phase 3
1,100
Akashi-shi, Chūōku, Hidaka-shi, Kashiwa, Kobe, Kōtoku, Kurume-shi, Nagoya
2025-12-29
Recruiting
Sanofi
Phase 2
144
Nagoya, Tsukuba, Koshigaya, Tokyo
2025-12-29
Active, closed
UCB Biopharma SRL
Phase 2
165
Habikino, Nagoya, Sakai, Sapporo, Tachikawa-shi, Yokohama
2025-12-29
Recruiting
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
NCT07288359Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
DrugsLetrozole·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
205
Kyoto
2025-12-29
Recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1/2
70
2025-12-26
Recruiting
Tongji Hospital
Phase 2
77
2025-12-25
Recruiting
Beijing Tide Pharmaceutical Co., Ltd
Phase 3
508
2025-12-24
Recruiting
Eli Lilly and Company
Phase 3
800
Bunkyō City, Chiba, Fukuoka, Fukushima, Hidaka, Hirakata, Hiroshima, Kagoshima
2025-12-22
Recruiting
Pilot Study: Effects of CCP Intervention on NICU Environment and Preterm Infants Development
NCT07306000Preterm Infant Development, Preterm Infant Health
Turku University Hospital
Not applicable
100
Matsumoto, Kyoto
2025-12-22
Recruiting
Otsuka Pharmaceutical Co., Ltd.
Phase 3
100
Fukuoka
2025-12-22
Recruiting
Taiho Oncology, Inc.
Phase 3
360
Nagoya, Kurume-Shi, Hiroshima, Sapporo, Fukuoka, Akashi, Kobe, Yokohama
2025-12-22
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 4
20
Bunkyō City, Hirakata-shi, Iruma-Gun, Kyoto, Matsumoto-shi, Miyazaki, Nagoya, Nara
2025-12-19
Recruiting
argenx
Phase 2
70
Tsukuba, Kawasaki-shi, Sendai, Hanamaki, Narita
2025-12-19
Recruiting
argenx
Observational
70
Tsukuba, Kawasaki-Shi, Sendai, Hanamaki, Narita
2025-12-19
Active, closed
Amgen
Phase 3
250
Chikushino-shi, Fukuoka, Aki-gun, Kitahiroshima-shi, Yokohama, Kumamoto, Urasoe-shi, Osaka
2025-12-19
Recruiting
Janssen Research & Development, LLC
Phase 3
800
Bunkyō City, Hirakata, Kanazawa, Kobe, Sagamihara, Sunto Gun, Yokohama
2025-12-19
Recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2
318
2025-12-18
Recruiting
ArriVent BioPharma, Inc.
Phase 3
480
Nagoya, Toyoake, Kashiwa, Kurume-Shi, Sapporo, Akashi-shi, Natori-shi, Niigata
2025-12-17
Active, closed
A Clinical Evaluation of AMJ-401
NCT07373353Ischemic Heart Disease (IHD)
Abbott Medical Devices
Not applicable
50
Toyoake, Tokyo, Kitakyushu, Shiwa-gun, Kamakura, Kawasaki, Miyazaki, Sakai
2025-12-17
Recruiting
AstraZeneca
Phase 2
320
Aomori, Bunkyō City, Fukuoka, Hamamatsu, Hitachi-Naka, Iizuka-shi, Kawachinagano-shi, Matsuyama
2025-12-15
Recruiting
TBE Zone 2 PMS in Japan
NCT07049913Aneurysm Thoracic, Dissection of Aorta, Thoracic, Trauma
W.L.Gore & Associates
Observational
200
Osaka
2025-12-15
Not yet open
Chunyan Ma
Observational
1,740
2025-12-15
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
DrugCetuximab
Revolution Medicines, Inc.
Phase 3
500
Yokohama, Chiba, Fukuoka, Kyoto, Tokyo
2025-12-15
Recruiting
Ming-an Yu
Not applicable
108
2025-12-15
Recruiting
Eli Lilly and Company
Phase 3
1,035
Chigasaki, Chūōku, Kamakura, Kasuya-gun, Kawaguchi, Kita-ku, Mihama-ku,Chiba City, Naha
2025-12-15
By invitation
A Computer Game for Postpartum Mental Health After Emergency Cesarean Birth
NCT07290127Post-traumatic Stress Disorder (PTSD), Postpartum Mental Health
Kyoto University, Graduate School of Medicine
Not applicable
120
Kyoto
2025-12-13
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Chūōku, Fukuoka, Hirosaki, Kanazawa, Kashiwa, Kawasaki, Kita-ku, Kobe
2025-12-12
Recruiting
GlaxoSmithKline
Phase 3
1,250
Gunma, Kagoshima
2025-12-12
Recruiting
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
NCT07144163Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 3
150
Hiroshima, Asahikawa, Kobe, Bunkyo-ku, Fuchu-shi, Setagaya-ku, Shinjuku-ku
2025-12-11
Recruiting
Shionogi
Phase 2
192
Kasugai-Shi, Nagoya-Shi Nakamura-Ku, Chikushino-shi, Fukuoka, Fukuoka-Shi Chuo-Ku, Fukuoka-Shi Hakata-Ku, Kitakyushu-Shi Yahatanishi-Ku, Kitakyushu-Shi
2025-12-11
Recruiting
DALY II Japan/MB-CART2019.1 for DLBCL
NCT07288879DLBCL - Diffuse Large B Cell Lymphoma, CAR T Cell Therapy
DrugZamtocabtagene autoleucel
Miltenyi Biomedicine GmbH
Phase 2
31
Tokyo
2025-12-11
Recruiting
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
NCT07326215Acute Respiratory Distress Syndrome, Acute Kidney Injury
Vantive Health LLC
Not applicable
99
2025-12-11
Recruiting
Pfizer
Phase 3
800
Nagoya, Chiba, Kashiwa, Yokohama, Hidaka, Kitaadachi-gun, Nagaizumi-cho, Koto-ku
2025-12-11
Recruiting
Pfizer
Phase 3
32,500
Nagoya, Iizuka-shi, Itoshima, Kitakyushu-shi, Onga-gun, Koga, Kumamoto, Ōmura
2025-12-10
Rows per page Showing 1–500 of 2516
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site. Derived from ClinicalTrials.gov. Retrieved 13 November 2026. https://priyalifescience.com/clinical-trials-japan

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,516 studies in total at the last sync on 12 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

How many clinical trials are recruiting in Japan?

1,285 of the 2,516 studies in this register are recruiting new participants as of the 12 Nov 2026, 03:19 UTC sync. A further 107 have not yet opened recruitment, 1,065 are active but closed to new participants, and 59 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase, 2,516 studies
PhaseStudiesRecruitingShare
Phase 31,09850343.6%
Phase 237418314.9%
Observational31918612.7%
Phase 12371229.4%
Phase 1/21761157%
Not applicable174916.9%
Phase 2/372452.9%
Phase 461382.4%
Early Phase 1520.2%

Most active sponsors

Lead sponsors with the most studies
Lead sponsorStudiesRecruiting
AstraZeneca19691
Eli Lilly and Company11866
Novartis Pharmaceuticals10650
AbbVie10041
Merck Sharp & Dohme LLC10050
Pfizer9956
Janssen Research & Development, LLC7832
GlaxoSmithKline7443
Bristol-Myers Squibb6943
China-Japan Friendship Hospital6945

This register, in your inbox every Friday

One email a week with how many trials are recruiting in Ireland, new EMA and FDA approvals and medicine shortages, built from the same public registers as this page.

Free. Unsubscribe from any email with one click. See our privacy policy.

→

Browse trials by condition

Multiple Myeloma (49) Breast Cancer (46) Obesity (42) Non-Small Cell Lung Cancer (39) Carcinoma, Non-Small-Cell Lung (32) Non-small Cell Lung Cancer (31) Crohn's Disease (26) Ulcerative Colitis (26) Solid Tumors (24) Overweight (23) Prostate Cancer (23) Systemic Lupus Erythematosus (22) Advanced Solid Tumor (22) Gastric Cancer (22) Ovarian Cancer (21)
→

Browse trials by site location

Fukuoka (557) Nagoya (513) Sapporo (400) Tokyo (375) Osaka (354) Chiba (328) Kashiwa (317) Yokohama (272) Kobe (239) Kyoto (231) Hiroshima (224) Sendai (207) Chūōku (202) Matsuyama (172) Bunkyō City (171)
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.